We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ignoring pleas from PhRMA, the FDA has decided to stay the paper pedigree requirements in the Prescription Drug Marketing Act of 1987 (PDMA) for another 32 months while it oversees industry's adoption of electronic pedigrees using track-and-trace technologies to combat the counterfeiting of Rx drugs.